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We have recently reported the possible imatinib-resistant
mechanism; long-term exposure of leukemia cells to imatinib
downregulated levels of phosphatase and tensin homolog
deleted on chromosome 10 (PTEN) via hypermethylation of its
promoter region (Leukemia 2010; 24: 1631). The present study
explored the molecular mechanisms by which imatinib caused
methylation on the promoter region of this tumor suppressor
gene in leukemia cells. Real-time reverse transcription PCR
found that long-term exposure of chronic eosinophilic leukemia
EOL-1 cells expressing FIP1L1/platelet-derived growth factor
receptor-a to imatinib induced expression of DNA methyltrans-
ferase 3A (DNMT3A) and histone-methyltransferase enhancer
of zeste homolog 2 (EZH2), a family of polycomb group, thereby
increasing methylation of the gene. Immunoprecipitation
assay found the increased complex formation of DNMT3A and
EZH2 proteins in these cells. Moreover, chromatin immunopre-
cipitation assay showed that amounts of both DNMT3A
and EZH2 proteins bound around the promoter region of PTEN
gene were increased in EOL-1 cells after exposure to imatinib.
Furthermore, we found that levels of DNMT3A and EZH2
were strikingly increased in leukemia cells isolated from
individuals with chronic myelogenous leukemia (n¼1) and
Philadelphia chromosome-positive acute lymphoblastic leuke-
mia (n¼2), who relapsed after treatment with imatinib com-
pared with those isolated at their initial presentation. Taken
together, imatinib could cause drug-resistance via recruitment
of polycomb gene complex to the promoter region of the PTEN
and downregulation of this gene’s transcripts in leukemia
patients.
Blood Cancer Journal (2011) 1, e48; doi:10.1038/bcj.2011.33;
published online 9 December 2011
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Introduction
Epigenetic states are determined by heritable patterns of changes
in chromatin and gene expression without underlying alterations
in DNA sequence.
1 The polycomb group (PcG) proteins and the
DNA methylation systems are intimately involved in heritable
repression of gene activity.
1,2 PcG protein enhancer of zeste
homolog 2 (EZH2), a family of histone methyltransferase,
catalyzes trimethylation at lysine 27 of histone H3
(H3K27me3), which serves as an anchorage point for the
recruitment of additional PcG proteins and contributes to
formation of a repressive chromatin state.
3,4 EZH2 works
together with other components such as embryonic ectoderm
development and suppressor of zeste 12 to form the polycomb
repressive complex 2, which interacted with target gene
promoters, thereby acting as a transcriptional repressor via
chromatin modiﬁcation.
5–7 Recent studies showed that knock-
down of EZH2 by RNA interference sensitized drug-resistant
ovarian cancer A2780/DDP cells to cisplatin in association with
inhibition of H3K27me3. Other studies found that aberrant
expression of EZH2 was associated with chemotherapy resis-
tance in cancer cells in vitro and in vivo.
8 In addition,
H3K27me3 was speciﬁcally associated with de novo methylated
CpG islands in cancer.
9 Thus, aberrant expression of PcG
proteins may be involved in both carcinogenesis and drug
resistance.
DNA methyltransferases (DNMTs), such as DNMT1,
DNMT3A and DNMT3B, are also key epigenetic regulators
involved in transcriptional repression.
10–12 DNMT3A and
DNMT3B are supposed to act as de novo methyltrans-
ferase, whereas DNMT1 acts to maintain methyltransferase
activity.
13 Notably, EZH2 interacted physically with the
DNMTs and facilitated their binding to the EZH2-target
gene myelin transcription factor 1 (MYT1) promoter, resulting
in MYT1 silencing. In addition, both embryonic ectoderm
development and suppressor of zeste 12 were shown to interact
with DNMTs and to be associated with DNMT enzymatic
activity.
14
Imatinib (Gleevec) dramatically improved survival of patients
with chronic myelogenous leukemia (CML) and Philadelphia-
positive acute lymphoblastic leukemia (Phþ ALL) by blocking
Abl activity and its downstream signaling.
15–18 In addition,
imatinib has been shown to be effective in a number of other
malignancies that are caused by activated receptor tyrosine
kinases, including chronic myelomonocytic leukemia
19 asso-
ciated with rearrangements of platelet-derived growth factor
receptor-b and chronic eosinophilic leukemia, a rare clonal
myeloproliferative disorder caused by FIP1L1/platelet-derived
growth factor receptor-a.
20,21 Development of resistance to
imatinib has recently emerged as an important clinical problem
in patients with leukemia, most often due to acquired mutations
in the target kinase.
22 However, the secondary mutation in the
target kinase cannot explain all cases of drug resistance.
23
Recently, we have identiﬁed hypermethylation on the promoter
region of the phosphatase and tensin homolog deleted on
chromosome 10 (PTEN) gene in association with downregula-
tion of this gene transcripts and activation of pro-survival
signaling mediated by AKT in imatinib-resistant leukemia cells
isolated from individuals with chronic eosinophilic leukemia,
CML and Phþ ALL.
24
This study explored molecular mechanisms by which
imatinib caused hypermethylation of PTEN in leukemia
cells. Received 6 June 2011; accepted 7 July 2011
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Cells
Chronic eosinophilic leukemia EOL-1 cells were obtained from
RIKEN BRC Cell Bank (Tsukuba, Japan). To establish imatinib-
resistant EOL-1 cells, imatinib (1nM) was added every 3 days for
upto 4 months to culture media. Leukemic peripheral blood or
bone marrow cells were isolated from individual with CML
(n¼1) and Phþ ALL (n¼2) after obtaining informed consent.
24
Chemicals
Imatinib and nilotinib were provided by Novartis (Basel,
Switzerland). Dasatinib was provided by Bristol-Myers Squibb
(New York, NY, USA). DNMT inhibitor 5-aza-20-deoxycytidine
(decitabine, 5-AzadC) was purchased from Sigma (St Louis,
MO, USA). These reagents were dissolved in 100% dimethyl
sulfoxide to a stock concentration 10mM and stored at  801C.
MTT assay
Cells (3 10
5 per ml) were cultured with various concentrations
of the indicated agents. After 2 days, cell viability was mea-
sured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay as previously described.
25 All experiments
were performed in triplicate and repeated at least three times.
RNA isolation and reverse transcription-PCR
RNA isolation and cDNA preparation were performed as
described previously.
26 We measured expression of 18S for
normalization as previously described.
26 Real-time PCR was
carried out by using Power SYBR Green PCR Master Mix
(Applied Biosystems, Warrington, UK) as described pre-
viously.
26 Primers for PCR are shown in Table 1. PCR conditions
for all genes were as follows: 951C initial activation for 10min
followed by 40 cycles of 951C for 15s and 601C for 60s, and
ﬂuorescence determination at the melting temperature of the
product for 20s on an ABI PRISM 7000 (Applied Biosystems).
Immunoprecipitations and western blot analysis
Whole cell lysates from EOL-1 cells were prepared utilizing
RIPA buffer and were immunoprecipitated with an anti-EZH2
(Cell Signaling Technology, Beverly, MA, USA) antibody and
protein G Sepharose (Pierce, Rockford, IL, USA). The precipi-
tated samples were subjected to western blot analysis.
The membrane was sequentially probed with anti-DNMT3a
(Abcam, Cambridge, UK), -EZH2 (Cell Signaling Technology)
and -trimethyl histone H3 (Lys27; Cell Signaling Technology)
antibodies.
Methylation analysis by methylation-speciﬁc PCR
DNA of 1mg isolated from EOL-1 cells was used for bisulﬁte
treatment done by the EZ DNA Methylation kit (Zymo Research,
Orange, CA, USA) according to the supplier’s protocol.
The primer sets used to amplify the promoter region of the
PTEN gene were described elsewhere.
24 Primers to amplify
other PCR products are shown in Table 1. Ampliﬁcation was
carried out in a Mycycler thermal cycler (Bio-Rad, Tokyo, Japan)
at 951C for 3min, cycled at 951C for 30s, 571C for 30s and
721C for 1min (40 cycles), followed by a 7min extension at
721C.
Chromatin immunoprecipitation assay
The cells (5 10
5 per ml) were incubated with imatinib (1nM).
After 4 months, formaldehyde was added to cells to a ﬁnal
concentration of 1%, and the cells were incubated at 371C for
20min. The cells were collected and subjected to chromatin
immunoprecipitation kit (Millipore, Temecula, CA, USA)
according to the manufacturer’s protocol. An anti-DNMT3A
(Abcam) or -EZH2 (Cell Signaling Technology) antibody was
used for immunoprecipitation. Immunoprecipitated DNA was
recovered and used as a template for real-time PCR. The primers
for the PTEN promoter were as follows: forward, 50-CGGGCGG
TGATGTGGC-30 reverse, 50-GCCTCACAGCGGCTCAACTCT-30.
Real-time PCR was carried out by using Power SYBR Green PCR
Master Mix (Applied Biosystems) as previously described.
24
The ampliﬁed sequences were normalized to those from
input (cross-linked DNA/protein complexes), which were not
immunoprecipitated with anti-DNMT3a and -EZH2 antibodies
as previously described.
24
Statistical analysis
When comparing two groups, Student’s t-test was used. All
statistical analyses were carried out using SPSS software (Version
11.03; SPSS, Tokyo, Japan), and the results were considered to
be signiﬁcant when the P-value was o0.05, and highly
signiﬁcant when the P-value was o0.01.
Results
The effect of imatinib on DNMTs and PcG proteins
We investigated whether short-term exposure (24–120h) of
EOL-1 cells to imatinib induced DNMTs, such as DNMT1,
DNMT3A and DNMT3B, by real-time reverse transcription PCR
(Figure 1a). Previous studies found that IC50 of imatinib against
EOL-1 cells was 0.3nM.
24 High dose of imatinib (1nM)
dramatically induced apoptosis in EOL-1 cells (data not shown)
and did not induce expression of these genes after short-term
incubation (Figure 1a). On the other hand, low dose of imatinib
(0.1nM) increased levels of DNMTs and PcG proteins such as
EZH2 and embryonic ectoderm development in EOL-1 cells by
96h (Figure 1a). This dose of imatinib (0.1nM, 96h) did not
signiﬁcantly inhibit the proliferation of EOL-1 cells, as assessed
by MTT assay (Figure 1b). However, low dose of imatinib
decreased their proliferation by approximately 60% after 120h
(Figure 1b) in parallel with disappearance of induction of
DNMTs and PcG proteins (Figure 1a). Similarly, relatively low
Table 1 PCR primers
Gene Direction Primer
DNMT1 Forward 50-ACCGCTTCTACTTCCTCGAGGCCTA-30
Reverse 50-GTTGCAGTCCTCTGTGAACACTGTGG-30
DNMT3A Forward 50-CACACAGAAGCATATCCAGGAGTG-30
Reverse 50-AGTGGACTGGGAAACCAAATACCC-30
DNMT3B Forward 50-AATGTGAATCCAGCCAGGAAAGGC-30
Reverse 50-ACTGGATTACACTCCAGGAACCGT-30
EZH2 Forward 50-TTCATGCAACACCCAACACT-30
Reverse 50-GGGCCTGCTACTGTTATTGG-30
EED Forward 50-GAGAGGGAAGTGTCGACTGC-30
Reverse 50-CCCAACTTTTCCTTCCAGGT-30
18S Forward 50-AAACGGCTACCACATCCAAG-30
Reverse 50-CCTCCAATGGATCCTCGTTA-30
Abbreviations: DNMT, DNA methyltranferase; EED, embryonic ecto-
derm development; EZH2, enhancer of zeste homolog 2.
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Blood Cancer Journalconcentration (less than IC50 dose) of dasatinib (1nM)
and nilotinib (10nM) increased the levels of DNMTs and
PcG proteins in these cells (Figures 1c and d). We next
attempted to establish imatinib-resistant EOL-1 cells by culturing
these cells in the presence of imatinib (1nM). Interestingly,
exposure of EOL-1 cells to imatinib (1nM) for 4 months
signiﬁcantly increased the levels of DNMTs and PcG proteins
(Figure 1e). As expression of these genes increased, EOL-1 cells
became resistant to imatinib-mediated growth inhibition
(Figure 1f).
EZH2 interacts with DNMT3A to repress PTEN
We examined whether levels of H3K27me3 were increased in
EOL-1 cells after exposure to imatinib (Figure 2a). As expected,
the levels of H3K27me3 increased after treatment with imatinib
for 3 months in EOL-1 cells in parallel with upregulation of
EZH2 (Figure 2a). Additional 1-month treatment of EOL-1 cells
with imatinib further increased levels of H3K27me3 in
conjunction with upregulation of EZH2 and DNMT3A
(Figure 2a). We next probed the interaction between imatinib-
induced DNMT3A and EZH2 by utilizing Immunoprecipitation
Figure 1 The effect of imatinib on DNMTs and PcG proteins. Real-time reverse transcription (RT)-PCR. (a, c, d) EOL-1 cells were cultured with
low dose of imatinib (0.1nM), dasatinib (1 or 10nM) and nilotinib (10 or 100nM) for the indicated time period. After incubation, EOL-1 cells were
harvested and RNA was extracted from EOL-1 cells after exposure to imatinib for the indicated time period. cDNAs were synthesized and
subjected to real-time RT-PCR to measure the levels of DNMT1, DNMT3A, DNMT3B, EZH2 and embryonic ectoderm development (EED). Results
represent the mean±s.d. of three experiments performed in triplicate. The statistical signiﬁcance was assessed by a paired t-test.
*Po0.01;**Po0.05. (b) EOL-1 cells (5 10
5 per ml) were seeded in 96-well plates and cultured with imatinib (0.1nM) for 24–120h. At the
indicated time point, their proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results
represent the mean±s.d. of three experiments performed in triplicate. (e) EOL-1 cells were cultured with high dose of imatinib (1nM) for up to
4 months. After incubation, EOL-1 cells were harvested and RNA was extracted from EOL-1 cells after exposure to imatinib for the indicated time
period. cDNAs were synthesized and subjected to real-time RT-PCR to measure the levels of DNMT1, DNMT3A, DNMT3B, EZH2 and EED.
Results represent the mean±s.d. of experiment performed in triplicate. The statistical signiﬁcance was assessed by a paired t-test.
*Po0.01;**Po0.05. MTT assay. (f) EOL-1 cells were cultured in the presence of imatinib (1nM) for up to 4 months. At the indicated time
point, either control or imatinib-treated EOL-1 cells (5 10
5 per ml) were seeded in 96-well plates and cultured with imatinib (1nM). After 48h,
proliferation was measured by MTT assay. Results represent the mean±s.d. of experiment performed in triplicate.
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DNMT3A in imatinib-resistant EOL-1 cells (Figure 2b). We
further examined whether DNMT3A and EZH2 bound to the
PTEN promoter in EOL-1 cells after treatment with imatinib
for 4 months, using chromatin immunoprecipitation assays
(Figure 2c). Both DNMT3A and EZH2 were enriched in the
PTEN promoter in these cells (Figure 2c). We next examined the
promoter region of PTEN gene to conﬁrm if epigenetic modiﬁca-
tion such as DNA hypermethylation occurred in EOL-1 cells by
utilizing methylation-speciﬁc PCR (Figure 2d). As shown in
Figure 2d, GpC island on the promoter region of the PTEN gene
was partially methylated after 3 months exposure to imatinib.
However, DNA methylation on the PTEN promoter region was
facilitated after 4 months exposure to imatinib (Figure 2d), when
the levels of PTEN were downregulated (Figure 2e). In conjunc-
tion with downregulation of this gene transcript, EOL-1 cells
became resistant to imatinib-mediated growth inhibition
(Figure 1e). Furthermore, we compared the levels of DNMT3A
and EZH2 mRNA in leukemia cells isolated from individuals with
CML (n¼1) and Phþ ALL (n¼2; Figure 2f) at the time of relapse
after imatinib treatment with those obtained at initial diagnosis.
Notably, the levels of both EZH2 and DNMT3A were increased
after treatment with imatinib in these cases (Figure 2f). We
previously showed hypermethylation on the promoter region of
the PTEN gene in association with downregulation of this gene
transcript in these cases.
24
DNMT inhibitor 5-AzadC downregulated the levels
of DNMTs in imatinib-resistant EOL-1 cells
We previously showed that an anti-epigenetic agent DNMT
inhibitor 5-AzadC restored PTEN expression, resulting in
sensitization of imatinib-resistant EOL-1 cells to imatinib.
27
The present study examined whether 5-AzadC downregulated
the levels of DNMTs in imatinib-resistant EOL-1 cells by
real-time reverse transcription-PCR. As expected, exposure of
these cells to 5-AzadC (1mM) potently decreased the levels
of DNMT3A, but not DNMT3B (Figure 3a). Immunoprecipita-
tion assay found that exposure of EOL-1 cells to 5-AzadC (1mM)
prevented interaction of EZH2 and DNMT3A proteins
(Figure 3b). At the same time, the methylation on the promoter
region of the PTEN was inhibited and the levels of PTEN mRNA
were increased by approximately two-fold (Figures 3c and d).
Discussion
The present study showed that long-term exposure of EOL-1
cells to imatinib increased the levels of both PcG proteins and
Figure 1 (Continued).
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H3K27me3 (Figure 2a). Imatinib-induced DNMT3A formed a
complex with EZH2 (Figure 2b), which facilitated their binding
to the PTEN promoter and induced DNA hypermethylation of
this region (Figures 2c and d), leading to downregulation of
PTEN (Figure 2e). Notably, the levels of both DNMT3A and
EZH2 were increased in imatinib resistant-leukemia cells
isolated from individuals with CML and Phþ ALL (Figure 2f).
We previously showed that levels of PTEN were downregulated
in these cells.
24 We therefore hypothesize that imatinib
treatment induced upregulation of DNMT3A and EZH2 in
leukemia cells, which caused downregulation of PTEN via
hypermethylation of the promoter region of this gene. PTEN is a
negative regulator of AKT, an important pro-survival signal
mediator. Downregulation of PTEN probably might cause AKT,
which causes drug-resistance to imatinib (Figure 4).
24
Importantly, exposure of EOL-1 cells to low dose of second-
generation tyrosine kinase inhibitors dasatinib and nilotinib also
Figure 2 EZH2 interacts with DNMT3A in imatinib-resistant EOL-1 cells. Western blot analysis. (a) EOL-1 cells were cultured with imatinib (1nM)
for 3 or 4 months. Cells were harvested and subjected to western blot analysis to monitor the levels of tri-methyl-histone H3 (Lys27), histone H3,
EZH2 and DNMT3A. Each lane was loaded with 20mg of nuclear protein lysates. Levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
were measured as a loading control. Band intensities were quantiﬁed with ImageJ software (Wayne Rasband, NIH). Immunoprecipitation.
(b) EOL-1 cells were cultured with imatinib (1nM) for 3 or 4 months. Cells were harvested and proteins were extracted. The EZH2 proteins were
immunoprecipitated and subjected to western blot analysis. The membrane was probed sequentially with anti-DNMT3A (top) and anti-EZH2
antibodies (bottom). Binding of EZH2 and DNMT3A in PTEN promoter region. Chromatin immunoprecipitation assay. (c) Binding of DNMT3A and
EZH2 in the PTEN promoter was analyzed by ChIP assay. To quantify acetylated DNA precisely, we employed real-time PCR. The ampliﬁed
sequences were normalized to those from input (the cross-linked DNA/protein complexes, which were not immunoprecipitated with anti-
DNMT3A and -EZH2 antibodies). Results represent the mean±s.d. of two experiments performed in duplicate. The statistical signiﬁcance was
assessed by a paired t-test. *Po0.01;**Po0.05. ChIP, chromatin immunoprecipitation. Methylation-speciﬁc PCR. (d) DNA was extracted from
EOL-1 cells. DNA with methylated CpG was processed using the EZ DNA Methylatiohn Kit. The recovered DNA was ampliﬁed by PCR on
methylation of the PTEN promoter. The 162-bp product indicates an unmethylation, whereas the 206-bp product indicates a methylation. Real-
time reverse transcription-PCR. (e) RNA was extracted from EOL-1 cells. cDNAs were synthesized and subjected to real-time RT-PCR to measure
the levels of PTEN. Results represent mean ± s.d. of duplicate cultures. *Po0.05; **Po0.01. Real-time RT-PCR. (f) RNA was extracted from
peripheral blood mononuclear cells or bone marrow of CML (n¼1) and Phþ ALL (n¼2) patients before and after treatment. cDNAs were
synthesized and subjected to real-time RT-PCR to measure the levels of PTEN. Results represent mean±s.d. of duplicate cultures. *Po0.05;
**Po0.01.
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Figure 3 5-AzadC inhibits the interaction of between DNMT3A and EZH2 in imatinib-resistant EOL-1 cells. Real-time reverse transcription-PCR.
(a) EOL-1 cells were cultured with 5-AzadC (1mM). After 72h, cells were harvested and RNA was extracted. cDNAs were synthesized and
subjected to real-time RT-PCR to measure the levels of DNMTs. Results represent the mean ± s.d. of three experiments performed in triplicate. The
statistical signiﬁcance was assessed by a paired t-test. *Po0.01;**Po0.05. Aza, 5-AzadC. Immunoprecipitation. (b) EOL-1 cells were cultured
with 5-AzadC (1mM). After 72h, cells were harvested and proteins were extracted. The EZH2 protein was immunoprecipitated and subjected to
western blot analysis. The membrane was probed sequentially with an anti-DNMT3A antibody (top) and an anti-EZH2 (bottom). Aza, 5-AzadC.
Methylation-speciﬁc PCR. (c) DNA was extracted from EOL-1 cells. DNA with methylated CpG was processed using the EZ DNA Methylatiohn Kit.
The recovered DNA was ampliﬁed by PCR on methylation of the PTEN promoter. The 162-bp product indicates an unmethylation, whereas the
206-bp product indicates a methylation. Real-time RT-PCR. (d) RNA was extracted from EOL-1 cells. cDNAs were synthesized and subjected to
real-time RT-PCR to measure the levels of PTEN. Results represent mean±s.d. of duplicate cultures. *Po0.05; **Po0.01. Aza, 5-AzadC.
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Thus, induction of genes involved in transcriptional repression
may be universal events among this class of kinase inhibitors.
Other studies have recently shown that the drug resistance in
lung cancer cells induced by the tyrosine kinase inhibitors
erlotinib was dependent on epigenetic mechanisms. Erlotinib
increased levels of histone demethylase such as Jumonji AT-rich
interactive domain-1A, and caused global changes in the
chromatin state in the cells.
27 The drug resistance against
tyrosine kinase inhibitors could be overcome by treatment with
an anti-epigenetic agent histone deacetylase inhibitor, high-
lighting a potential therapeutic strategy.
27 In fact, we previously
showed that histone deacetylase inhibitor successfully over-
came imatinib resistance in EOL-1R cells in association with
restoration of PTEN expression.
24 In addition, the present study
demonstrated that an anti-epigenetic agent 5-AzadC down-
regulated the levels of DNMT3A (Figure 3a) and inhibited its
binding to EZH2 (Figure 3b) in imatinib-resistant EOL-1 cells,
which probably mediated restoration of PTEN expression in
these cells.
24
EZH2 is essential for DNMTs to bind to the EZH2-target
promoters such as MYT1, KCNA1 and cannabinoid receptor 1
(CNR1), and silences expression of these genes.
14 Imatinib
increased levels of both EZH2 and DNMT3A in leukemia cells
(Figure 2a), which probably caused global epigenetic aberra-
tions and downregulated the expression of important
genes involved in regulation of cell growth, apoptosis and drug
metabolism, which could relate to acquisition of drug
resistance.
Taken together, long-term exposure of leukemia cells to
imatinib induced expression of PcG protein EZH2 and
DNMT3A, which probably silenced the PTEN gene expression.
Anti-epigenetic agents could be useful to overcome drug
resistance in individuals who receive tyrosine kinase inhibitors.
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